Floatz logo

INCOBOTULINUMTOXINA

Migraine Disorder

Uniformed Services University of the Health Sciencesprotein_peptidePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

100 Active assets in the Migraine Disorder cohort.

Asset / SponsorPhaseRating
Atogepant
Stanford University
Phase 4A
Rizatriptan
Antonios Likourezos
Phase 4A
Zolmitriptan
Zosano Pharma Corporation
Phase 4A
Naproxen
IRCCS San Raffaele Roma
Phase 4A
Eptinezumab
Stanford University
Phase 4BBB

View all 50 →

Same molecule, other indications

INCOBOTULINUMTOXINA is also rated in:

stroke disorderDormant
BBB
Indicative · Phase 4
78 / 100
View asset →
Parkinson diseaseDormant
BB
Indicative · Phase 3
69 / 100
View asset →
traumatic brain injuryActive
B
Indicative · Phase 3
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →